Similarly, fibroblast activation protein (FAP)-targeted radiopharmaceuticals that bind to tumour-associated fibroblasts, which are increased in dedifferentiated and more aggressive DTCs, have also been investigated [76,88]. The gene discussed is FAP; the disease is neoplasm.